Foundayo Cut Cardiovascular Risk in Type-2 Diabetes Study
The experimental drug lowered major heart-related risks for adults with Type-2 diabetes compared to insulin glargine.
Updated on Oct. 1, 2026 in Diabetes
Live Poll
Do you believe that new prescription weight-loss medications will lead to better health outcomes for patients?
In a recent Phase 3 clinical trial, Eli Lilly reported that the drug Foundayo led to a 16% lower risk of cardiovascular events in patients with Type-2 diabetes. The findings provide new data for those managing metabolic health and obesity alongside diabetes.
Why it matters
Managing cardiovascular complications is a critical priority for people living with Type-2 diabetes. This study offers a comparison against standard insulin treatment, providing clinicians with additional information to consider when tailoring long-term care plans.
A Phase 3 trial compared Foundayo to insulin glargine in participants with obesity and Type-2 diabetes. Findings at 52 weeks showed a 16% reduction in major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, compared to the insulin group.
The players
Eli Lilly
A pharmaceutical company focused on the development of treatments for metabolic conditions including obesity and diabetes.
The details
Foundayo aims to manage weight and blood glucose levels, which are central to mitigating cardiovascular stress in metabolic disorders. Participants in the study also saw secondary health improvements, including a 7-centimeter reduction in waist circumference and lower systolic blood pressure at week 52. These physical changes likely contribute to the overall reduction in heart-related risk factors measured during the trial.
Timeline
Week 52 marked the period when researchers measured waist circumference and blood pressure reductions.
Health Landscape
This development contributes to the ongoing evolution of diabetes care, shifting the focus from glucose control alone toward comprehensive cardiovascular protection. It joins a growing body of research, much like the SUSTAIN-6 clinical trial, that seeks to define the cardiovascular safety profile of metabolic therapies.
If you are managing Type-2 diabetes and obesity, these findings highlight the importance of discussing cardiovascular health with your physician. Ask your healthcare provider about how current treatment options compare to evolving therapies in reducing risks like heart attack and stroke.
The takeaway
Foundayo demonstrated a 16% lower risk of cardiovascular events compared to insulin glargine in a recent 52-week study. Discuss your current cardiovascular risk profile and metabolic health goals with your physician to ensure your treatment plan remains up to date.
Further reading
For a broader look at how researchers assess heart health in metabolic conditions, visit the Diabetes section.
Live Poll
Do you believe that new prescription weight-loss medications will lead to better health outcomes for patients?
